A Prospective, Single-blinded, Multi-center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-eluting Stent (MiStent System) in the Treatment of Patients With Coronary Heart Disease
Phase of Trial: Phase III
Latest Information Update: 21 Dec 2016
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Registrational; Therapeutic Use
- Acronyms DESSOLVE-C
- Sponsors Micell Technologies
- 15 Dec 2016 Planned End Date changed from 1 Dec 2020 to 1 Apr 2022.
- 15 Dec 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2018.
- 31 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.